Company Filing History:
2 out of 206 
1 out of 16,338 
Years Active: 1993-1996
Title: The Innovative Mind of Mary K VanAtten
Introduction: Mary K VanAtten, based in Wilmington, Delaware, has made significant contributions to the field of pharmacology through her innovations in antihypertensive agents. With a total of three patents to her name, her work primarily focuses on imidazole substitutions as angiotensin II antagonists, showcasing her expertise and dedication to improving healthcare.
Latest Patents: VanAtten's most recent patents include novel substituted imidazoles utilized as angiotensin II antagonists. One of her significant patents describes a compound represented by the formula (I), highlighting its potential application in managing hypertension. Another notable patent details a substituted imidazole of formula (III), further emphasizing its therapeutic advantages. A prime example of her work is the compound 1-((2'-((i-Amyloxycarbonylamino)sulfonyl)-3-fluoro-(1,1'-biphenyl)-4-yl)methyl)-5-[2-(N-butyryl-N-pyridin-3-ylamino)ethylcarbonyl]-4-ethyl-2-propyl-1H-imidazole, illustrating the complexity and innovative nature of her developments.
Career Highlights: Throughout her career, Mary K VanAtten has collaborated with some esteemed organizations in the pharmaceutical sector, including the Dupont Merck Pharmaceutical Company and E.I. du Pont de Nemours and Company. Her work has significantly influenced the pharmaceutical landscape, particularly in the development of antihypertensive medications that provide better patient outcomes.
Collaborations: In her journey, VanAtten has partnered with notable colleagues such as John J Duncia and Carol L Ensinger. These collaborations have played a crucial role in enhancing her research and contributing to the successful development of her patented compounds.
Conclusion: Mary K VanAtten stands out as a remarkable inventor whose work in the field of antihypertensive agents has advanced medical science. Her innovative spirit and commitment to research continue to inspire new approaches in pharmacology, ensuring her legacy will impact the industry for years to come.